NCT04003610 2025-11-04Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)Incyte CorporationPhase 2 Terminated7 enrolled 10 charts
NCT02872714 2025-08-14A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)Incyte CorporationPhase 2 Completed263 enrolled 20 charts